二トシル酸ラパチニブ HYDRATE

二トシル酸ラパチニブ HYDRATE 価格 もっと(2)

メーカー	製品番号	製品説明	CAS番号	包装	価格	更新時間	購入
富士フイルム和光純薬株式会社(wako)	W01MAS090594	二トシル酸ラパチニブ hydrate Lapatinib ditosylate hydrate	388082-78-8	250mg	￥260800	2024-03-01	購入
富士フイルム和光純薬株式会社(wako)	W01MAS090594	二トシル酸ラパチニブ hydrate Lapatinib ditosylate hydrate	388082-78-8	1g	￥579600	2024-03-01	購入

二トシル酸ラパチニブ HYDRATE 化学特性,用途語,生産方法

効能

抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬

商品名

タイケルブ (ノバルティスファーマ)

使用

Lapatinib ditosylate monohydrate is a form of Lapatinib I, an orally active drug for breast cancer as a dual EGFR and erbB-?2 inhibitor.

一般的な説明

Lapatinib is available in 250-mg tablets for oral administrationand is used in combination with cabecitabine in thetreatment of breast cancer for those patients that over expressthe type 2 EGF-R and who have previously receivedtaxane, anthracycline, and trastuzumab therapy. The type 2EGF-R is one subtype of this receptor and is also known asHER2 or ErbB-2. The agent is a receptor TK inhibitor targetingthe ErbB-1 and ErbB-2 subtypes. Binding occurs atthe ATP-binding site and thereby prevents phosphorylationand the subsequent activation of other kinase enzymes.ErbB-1 overexpression occurs in approximately27% to 30% of breast cancers, while ErbB-2 is over expressedin 20% to 25% of cases.The agent has demonstratedIC50 values of ＜0.2μM against ErbB-1 and 2 fromseveral different cancer cell lines and dissociates slowly(t_1/2＝300 min) from these receptor TKs.The drug isboth a substrate and an inhibitor of the efflux transportersPgp and BCRP. It is also an inhibitor of the hepatic uptaketransporter OATP1B1, which is an organic anion transporter.The absorption of lapatinib is incomplete andvariable after oral administration. The agent is extensivelymetabolized by CYP3A4 and CYP3A5, with minor contributionsfrom CYP2C19 and CYP2C8. Lapatinib inhibitsCYP3A and CYP2C8 at clinically relevant concentrations.The agent is highly (99%) protein bound and eliminatedprimarily in the feces. The half-life of the agent increaseupon repeated dosing, taking 6 days to reach steady statethat gives an effective half-life of 24 hours. The most commonlyseen adverse effects of lapatinib therapy are skinrash and diarrhea. Skin rash is commonly seen with manyof the other TK inhibitors and agents that target ErbB-1.Lapatinib-induced diarrhea is usually mild to moderate.There have been reports of decreases in left ventricularejection fraction associated with the agent, although thisappears to occur only rarely and is reversible upon discontinuationof therapy.

二トシル酸ラパチニブ HYDRATE 上流と下流の製品情報

原材料

準備製品

二トシル酸ラパチニブ HYDRATE 生産企業

名前	電話番号	電子メール	国籍	製品カタログ	優位度
Hebei Chuanghai Biotechnology Co., Ltd	+86-15531157085; +8615531157085	abby@chuanghaibio.com	China	8807	58
Hebei Mujin Biotechnology Co.,Ltd	+86 13288715578 +8613288715578	sales@hbmojin.com	China	12788	58
Hebei Yanxi Chemical Co., Ltd.	+8617531153977	allison@yan-xi.com	China	5854	58
HangZhou RunYan Pharma Technology Co.,LTD.	+8618882027439	sales2@runyanpharma.com	China	302	58
SHANDONG BOYUAN PHARMACEUTICAL CO., LTD.	+86-0531-69954981 +8615666777973	dwyane.wang@boyuanpharm.com	China	183	58
hebei hongtan Biotechnology Co., Ltd	+852-6619 3215 +86-17731935328	sales03@chemcn.cn	China	970	58
Apeloa production Co.,Limited	+8619933239880	admin@apcl.com.cn	China	861	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	485	58
Capot Chemical Co.,Ltd.	+86-（0）57185586718 +86-13336195806	sales@capot.com	China	29730	60
Beijing Cooperate Pharmaceutical Co.,Ltd	010-60279497	sales01@cooperate-pharm.com	CHINA	1803	55

388082-78-8(二トシル酸ラパチニブ HYDRATE)キーワード:

---

• 388082-78-8
• benzenesulfonic acid: N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6 -[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine: h ydrate
• N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
• Lapatinib Ditosilate
• Lapatinib, Tykerb, GW572016
• Lapatinib Ditosylate (GW-572016)
• lapatinib(GW572016)
• Lapatinib ditosylate hydrate
• bis(N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine) tetrakis(4-Methylbenzenesulfonate) hydrate
• Lapatinb
• 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate (9CI)
• Lapatinib ditosylate Monohydrate
• Rapatinib bis - toluene sulfonate
• GW-572016;GW572016
• Lapatinib xylene sulfonate
• N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1)
• Lapatinib Ditosylate MonohydrateI
• N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate) monohydrate
• Lapatinib ditosylate hydrat
• 4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, bis(4-Methylbenzenesulfonate), Monohydrate
• xyene sulfonate lapatinib
• (N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(Methylsulfonyl)ethylaMino)Methyl)furan-2-yl)quinazolin-4-aMine)bis(4-Methylbenzenesulfonate) hydrate
• Lapatinib ditosylate N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine bis(4-methylbenzenesulfonate)
• N-(3-Chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)-quinazolin-4-ylamine ditosylate hydrate
• Lapatinib ditoluenesulfonate monohydrate
• Lapatinib tosilate
• Lapatinib tosilate hydrate
• Lapatinib ditosylate ISO 9001：2015 REACH
• Lapatinib D4 DitosylateQ: What is Lapatinib D4 Ditosylate Q: What is the CAS Number of Lapatinib D4 Ditosylate
• Lapatinib p-toluenesulfonate monohydrate
• GW2016 ditosylate
• 二トシル酸ラパチニブ HYDRATE
• 二トシル酸ラパチニブ MONOHYDRATE
• ラパチニブトシル酸塩水和物
• ラパチニブトシル酸塩水和物 (JAN)
• ラパチンB
• (-)-ラバチンB
• (1S,4S,13S)-1,2-ジヒドロスピロ[1,4-エタノ-6H-ピラジノ[2,1-b]キナゾリン-13,3′(2′H)-[1H]インドール]-2′,3,6(4H)-トリオン
• (4S)-1α,4α-[[(S)-2-オキソインドリン-3,3-ジイル]メチレン]-1,3,4,6-テトラヒドロ-2H-ピラジノ[2,1-b]キナゾリン-3,6-ジオン
• (1'S,3S,12'S)-1,2-ジヒドロ-2',10',16'-トリアザスピロ[インドール-3,13'-テトラシクロ[10.2.2.02,11.04,9]ヘキサデカン]-4',6',8',10'-テトラエン-2,3',15'-トリオン
• (13S)-1,2-ジヒドロスピロ[1α,4α-エタノ-6H-ピラジノ[2,1-b]キナゾリン-13,3′(2′H)-[1H]インドール]-2′,3,6(4H)-トリオン